Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies

• Published in: Pharmaceutics Vol. 10; no. 4; p. 202
• Main Authors: Vallet, Sonia, Filzmoser, Julia-Marie, Pecherstorfer, Martin, Podar, Klaus
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 24-10-2018; MDPI
• Subjects: Adipocytes; bisphosphonates; Bone diseases; Bone marrow; Cell growth; Collagen; Cytokines; denosumab; Drug resistance; Hypercalcemia; Ligands; Magnetic resonance imaging; Mortality; Multiple myeloma; osteolytic bone disease; Pathogenesis; Peptides; Plasma; Proteins; Review; Transcription factors; Wnt inhibitors; multiple myeloma; bisphosphonates; Wnt inhibitors; denosumab; osteolytic bone disease
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics10040202

Bone disease, including osteolytic lesions and/or osteoporosis, is a common feature of multiple myeloma (MM). The consequences of skeletal involvement are severe pain, spinal cord compressions, and bone fractures, which have a dramatic impact on patients' quality of life and, ultimately, survival. During the past few years, several landmark studies significantly enhanced our insight into MM bone disease (MBD) by identifying molecular mechanisms leading to increased bone resorption due to osteoclast activation, and decreased bone formation by osteoblast inhibition. Bisphosphonates were the mainstay to prevent skeletal-related events in MM for almost two decades. Excitingly, the most recent approval of the receptor activator of NF-kappa B ligand (RANKL) inhibitor, denosumab, expanded treatment options for MBD, for patients with compromised renal function, in particular. In addition, several other bone-targeting agents, including bone anabolic drugs, are currently in preclinical and early clinical assessment. This review summarizes our up-to-date knowledge on the pathogenesis of MBD and discusses novel state-of-the-art treatment strategies that are likely to enter clinical practice in the near future.